Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study.

Hdl Handle:
http://hdl.handle.net/10147/207832
Title:
Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study.
Authors:
Kennelly, S P; Abdullah, L; Paris, D; Parish, J; Mathura, V; Mullan, M; Crawford, F; Lawlor, B A; Kenny, R A
Affiliation:
St. James Hospital, Dublin, Ireland. skennelly1976@hotmail.com
Citation:
Int J Geriatr Psychiatry. 2011 Oct;26(10):1038-45. doi: 10.1002/gps.2638. Epub, 2010 Oct 29.
Journal:
International journal of geriatric psychiatry
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207832
DOI:
10.1002/gps.2638
PubMed ID:
21905098
Abstract:
BACKGROUND: Nilvadipine may lower rates of conversion from mild-cognitive impairment to Alzheimer's disease (AD), in hypertensive patients. However, it remains to be determined whether treatment with nilvadipine is safe in AD patients, given the higher incidence of orthostatic hypotension (OH) in this population, who may be more likely to suffer from symptoms associated with the further exaggeration of a drop in BP. OBJECTIVE: The aim of this study was to investigate the safety and tolerability of nilvadipine in AD patients. METHODS: AD patients in the intervention group (n = 56) received nilvadipine 8 mg daily over 6-weeks, compared to the control group (n = 30) who received no intervention. Differences in systolic (SBP) and diastolic (DBP) blood pressure, before and after intervention, was assessed using automated sphygmomanometer readings and ambulatory BP monitors (ABP), and change in OH using a finometer. Reporting of adverse events was monitored throughout the study. RESULTS: There was a significant reduction in the SBP of treated patients compared to non-treated patients but no significant change in DBP. Individuals with higher initial blood pressure (BP) had greater reduction in BP but individuals with normal BP did not experience much change in their BP. While OH was present in 84% of the patients, there was no further drop in BP recorded on active stand studies. There were no significant differences in adverse event reporting between groups. CONCLUSION: Nilvadipine was well tolerated by patients with AD. This study supports further investigation of its efficacy as a potential treatment for AD.
Language:
eng
MeSH:
Aged; Aged, 80 and over; Alzheimer Disease/*drug therapy; Antihypertensive Agents/*adverse effects; Blood Pressure/*drug effects; Female; Humans; Male; Middle Aged; Nifedipine/adverse effects/*analogs & derivatives
ISSN:
1099-1166 (Electronic); 0885-6230 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorKennelly, S Pen_GB
dc.contributor.authorAbdullah, Len_GB
dc.contributor.authorParis, Den_GB
dc.contributor.authorParish, Jen_GB
dc.contributor.authorMathura, Ven_GB
dc.contributor.authorMullan, Men_GB
dc.contributor.authorCrawford, Fen_GB
dc.contributor.authorLawlor, B Aen_GB
dc.contributor.authorKenny, R Aen_GB
dc.date.accessioned2012-02-01T10:45:58Z-
dc.date.available2012-02-01T10:45:58Z-
dc.date.issued2012-02-01T10:45:58Z-
dc.identifier.citationInt J Geriatr Psychiatry. 2011 Oct;26(10):1038-45. doi: 10.1002/gps.2638. Epub, 2010 Oct 29.en_GB
dc.identifier.issn1099-1166 (Electronic)en_GB
dc.identifier.issn0885-6230 (Linking)en_GB
dc.identifier.pmid21905098en_GB
dc.identifier.doi10.1002/gps.2638en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207832-
dc.description.abstractBACKGROUND: Nilvadipine may lower rates of conversion from mild-cognitive impairment to Alzheimer's disease (AD), in hypertensive patients. However, it remains to be determined whether treatment with nilvadipine is safe in AD patients, given the higher incidence of orthostatic hypotension (OH) in this population, who may be more likely to suffer from symptoms associated with the further exaggeration of a drop in BP. OBJECTIVE: The aim of this study was to investigate the safety and tolerability of nilvadipine in AD patients. METHODS: AD patients in the intervention group (n = 56) received nilvadipine 8 mg daily over 6-weeks, compared to the control group (n = 30) who received no intervention. Differences in systolic (SBP) and diastolic (DBP) blood pressure, before and after intervention, was assessed using automated sphygmomanometer readings and ambulatory BP monitors (ABP), and change in OH using a finometer. Reporting of adverse events was monitored throughout the study. RESULTS: There was a significant reduction in the SBP of treated patients compared to non-treated patients but no significant change in DBP. Individuals with higher initial blood pressure (BP) had greater reduction in BP but individuals with normal BP did not experience much change in their BP. While OH was present in 84% of the patients, there was no further drop in BP recorded on active stand studies. There were no significant differences in adverse event reporting between groups. CONCLUSION: Nilvadipine was well tolerated by patients with AD. This study supports further investigation of its efficacy as a potential treatment for AD.en_GB
dc.language.isoengen_GB
dc.subject.meshAgeden_GB
dc.subject.meshAged, 80 and overen_GB
dc.subject.meshAlzheimer Disease/*drug therapyen_GB
dc.subject.meshAntihypertensive Agents/*adverse effectsen_GB
dc.subject.meshBlood Pressure/*drug effectsen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshHumansen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.meshNifedipine/adverse effects/*analogs & derivativesen_GB
dc.titleDemonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study.en_GB
dc.contributor.departmentSt. James Hospital, Dublin, Ireland. skennelly1976@hotmail.comen_GB
dc.identifier.journalInternational journal of geriatric psychiatryen_GB
dc.description.provinceLeinster-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.